logo

For the Inventor, By the Inventor

The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Patent No.:

US 10378062 B1

PDFFull Text
Expired
Date of Patent:
Aug. 13, 2019

Filed:

Jun. 06, 2016

Natural-killer/t-cell lymphoma (nktcl) susceptibility prediction, diagnosis and therapy

Applicant:

Singapore Health Services Pte Ltd, Singapore, SG;

Inventors:

Bin Tean Teh, Singapore, SG;

Soon Thye Lim, Bowyer Block, SG;

Choon Kiat Ong, Singapore, SG;

Assignee:

SINGAPORE HEALTH SERVICES PTE LTD, Singapore, SG;

Attorneys:

Lathrop Gage LLP

Brian C. Trinque

Primary Examiner:

Sean E Aeder

Int. Cl.
CPC ...
C12Q 1/68 (2018.01); C12Q 1/6886 (2018.01); A61K 31/519 (2006.01); G01N 33/50 (2006.01); G01N 33/574 (2006.01); A61K 31/277 (2006.01); A61K 31/165 (2006.01); A01K 67/027 (2006.01);
U.S. Cl.
CPC ...
C12Q 1/6886 (2013.01); A01K 67/0275 (2013.01); A61K 31/165 (2013.01); A61K 31/277 (2013.01); A61K 31/519 (2013.01); G01N 33/5011 (2013.01); G01N 33/57407 (2013.01); G01N 33/57426 (2013.01); A01K 2267/0331 (2013.01); C12Q 2600/156 (2013.01); C12Q 2600/158 (2013.01); G01N 2333/912 (2013.01); G01N 2333/91215 (2013.01); G01N 2800/50 (2013.01);
Abstract

Natural-KilleifT-Cell Lymphoma (NKTCL) susceptibility prediction, diagnosis and therapy. The invention relates to a method for predicting Natural Killer T-cell Lymphoma (NKTCL) susceptibility and/or diagnosing NKTCL in a subject comprising testing for JAK mutations. The invention also relates to a method of screening for candidate agents capable of treating NKTCL using a cell line comprising at least one JAK mutation. The invention includes an NKTCL animal model comprising at least one JAK mutation. The invention also includes JAK inhibitors for treating NKTCL.

Find Patent Forward Citations

Quick Actions:

Teh, Bin. (2019). Natural-killer/t-cell lymphoma (nktcl) susceptibility prediction, diagnosis and therapy (U.S. Patent No. 10378062). U.S. Patent and Trademark Office. https://idiyas.com/patent/badge/10378062

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Loading…